retatrutide clinical trial data weight loss Results: 24% in 48 Weeks Retatrutide dose: the complete guide – Drug retatrutide helps people lower

Published in NEJM 2023

When you feel full longer, you eat less

GLP-1RAs can cause gastroparesis, requiring anaesthesia precautions due to aspiration risk

Bile acids may stimulate insulin secretion via activation of FXR and inhibition of ATP-dependent K + channels (172)

While safety within the phase 3 program is sufficient for marketing authorization (although the risk of cardiovascular events should not exceed a hazard ratio of 1.8 according to a guidance document that was released by the FDA at that time), it is the post-marketing phase in which rare adverse events and any other potential safety risks are identified or resolved

In late 2023, tirzepatide surpassed dulaglutide as the second most commonly prescribed ADM